Read by QxMD icon Read

Cancer Or Neoplasm

X L Zhang, B Y Chen
No abstract text is available yet for this article.
February 12, 2019: Zhonghua Yi Xue za Zhi [Chinese medical journal]
(no author information available yet)
No abstract text is available yet for this article.
February 2019: Revista Brasileira de Ginecologia e Obstetrícia
Joanna M Cain
No abstract text is available yet for this article.
February 2019: Revista Brasileira de Ginecologia e Obstetrícia
Giancarlo Agnelli
New England Journal of Medicine, Volume 380, Issue 8, Page 781-783, February 2019.
February 21, 2019: New England Journal of Medicine
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, Sara M Tolaney, Steven J Isakoff, Jennifer R Diamond, Joyce O'Shaughnessy, Rebecca L Moroose, Alessandro D Santin, Vandana G Abramson, Nikita C Shah, Hope S Rugo, David M Goldenberg, Ala M Sweidan, Robert Iannone, Sarah Washkowitz, Robert M Sharkey, William A Wegener, Kevin Kalinsky
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors...
February 21, 2019: New England Journal of Medicine
Alok A Khorana, Gerald A Soff, Ajay K Kakkar, Saroj Vadhan-Raj, Hanno Riess, Ted Wun, Michael B Streiff, David A Garcia, Howard A Liebman, Chandra P Belani, Eileen M O'Reilly, Jai N Patel, Habte A Yimer, Peter Wildgoose, Paul Burton, Ujjwala Vijapurkar, Simrati Kaul, John Eikelboom, Robert McBane, Kenneth A Bauer, Nicole M Kuderer, Gary H Lyman
BACKGROUND: Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these patients is uncertain. METHODS: In this double-blind, randomized trial involving high-risk ambulatory patients with cancer (Khorana score of ≥2, on a scale from 0 to 6, with higher scores indicating a higher risk of venous thromboembolism), we randomly assigned patients without deep-vein thrombosis at screening to receive rivaroxaban (at a dose of 10 mg) or placebo daily for up to 180 days, with screening every 8 weeks...
February 21, 2019: New England Journal of Medicine
Dirk Lindenblatt, Mareike Horn, Claudia Götz, Karsten Niefind, Ines Neundorf, Markus Pietsch
The ubiquitously expressed Ser/Thr kinase CK2 is a key regulator in a variety of key processes in normal and malignant cells. Due to its distinctive anti-apoptotic and tumor-driving properties, elevated levels of CK2 have frequently been found in tumors of different origin. In recent years, development of CK2 inhibitors has largely been focused on ATP-competitive compounds; however, targeting the CK2α/CK2β interface has emerged as a further concept that might avoid selectivity issues. In order to address the CK2 subunit interaction site, we have synthesized halogenated CK2β-mimicking cyclic peptides modified with the cell-penetrating peptide sC18 to mediate cellular uptake...
February 20, 2019: ChemMedChem
R Xu, G M Centola, C Tanrikut
BACKGROUND: While the spermatotoxic properties of cancer treatments such as chemotherapy and radiation therapy are widely recognized, the effect of malignancy itself on male fertility is not clearly understood. OBJECTIVES: To determine whether malignancy is associated with diminished semen quality prior to spermatotoxic treatment among sperm bankers. MATERIALS AND METHODS: Retrospective database review of de-identified records was obtained for all episodes of sperm banking performed at a cryobank from January 2004 to May 2017 for one of the following reasons: 'future use' (e...
February 20, 2019: Andrology
Lisa Morrissey, Megan Lurvey, Courtney Sullivan, Julia Challinor, Peter W Forbes, Linda Abramovitz, Glenn M Afungchwi, Rachel Hollis, Sara Day
BACKGROUND: In 2014, a task force of the International Society of Paediatric Oncology (SIOP) Paediatric Oncology in Developing Countries Nursing Workgroup published six baseline standards to provide a framework for pediatric oncology nursing care in low- and lower-middle income countries (L/LMIC). We conducted an international survey in 2016-2017 to examine the association between country income level and nurses' resporting of conformity to the standards at their respective institutions...
February 20, 2019: Pediatric Blood & Cancer
W P A Boellaard, A J M Gillis, G J L H van Leenders, H Stoop, T van Agthoven, L C J Dorssers, M Dinkelman-Smit, J L Boormans, L H J Looijenga
BACKGROUND: The microRNA-371a-3p (miR-371a-3p) has been reported to be an informative liquid biopsy (serum and plasma) molecular biomarker for both diagnosis and follow-up of patients with a malignant (testicular) germ cell tumor ((T)GCT). It is expressed in all histological cancer elements, with the exception of mature teratoma. However, normal testis, semen, and serum of males with a disrupted testicular integrity without a TGCT may contain miR-371a-3p levels above threshold, of which the cellular origin is unknown...
February 20, 2019: Andrology
Donna L Johnston, Susan Zupanec, Darcy Nicksy, Daniel Morgenstern, Aru Narendran, Rebecca J Deyell, Yvan Samson, Bing Wu, Sylvain Baruchel
BACKGROUND: Melatonin is a natural health product used for sleep disturbances. In preliminary studies of adults with advanced cancer, 20 mg of melatonin daily was associated with reduction in anorexia and weight loss-symptoms that also impact pediatric oncology patients. High doses of melatonin have not been studied in pediatrics. METHODS: This was a multicenter single-arm phase I dose-escalation study utilizing a 3 + 3 design to determine the safety and tolerability of escalating doses of melatonin in pediatric oncology patients with relapsed solid tumors...
February 20, 2019: Pediatric Blood & Cancer
Tsugumichi Koshinaga, Tetsuya Takimoto, Hajime Okita, Yukichi Tanaka, Eisuke Inoue, Takaharu Oue, Miwako Nozaki, Kunihiko Tsuchiya, Masayuki Haruta, Yasuhiko Kaneko, Masahiro Fukuzawa
BACKGROUND: Persistence of blastemal components after chemotherapy is a marker of poor outcome in Wilms tumor. Recent reports from local Japanese areas have described prechemotherapy blastemal predominant type Wilms tumor to be also a risk factor for relapse. However, significance of blastemal predominant WT remains to be evaluated in a larger study. This study aimed to retrospectively evaluate the prognostic significance of prechemotherapy blastemal predominant type Wilms tumor in the Japan Wilms tumor Study (JWiTS) trials...
February 20, 2019: Pediatrics International: Official Journal of the Japan Pediatric Society
Ali Zarei, Vahid Razban, Seyed Ebrahim Hosseini, Seyed Mohammad Bagher Tabei
AIMS: Set of unique sequences in bacterial genomes, responsible for protecting bacteria against bacteriophages, have been recently used for genetic manipulation of specific points in the genome. These system comprises of one RNA component and one enzyme component, known as CRISPR and Cas9, respectively. The present review focuses on the applications of the CRISPR/Cas9 technology in the development of cellular and animal models of human disease. DISCUSSION: Making a desired genetic alteration depend on the design of RNA molecules that guide endonucleases to a favorable genomic location...
February 20, 2019: Journal of Gene Medicine
Jianming Wu, Hemant K Mishra, Bruce Walcheck
Human NK cell antitumor activities involve Ab-dependent cell-mediated cytotoxicity (ADCC), which is a key mechanism of action for several clinically successful tumor-targeting therapeutic mAbs. Human NK cells exclusively recognize these Abs by the Fcγ receptor CD16A (FcγRIIIA), one of their most potent activating receptors. Unlike other activating receptors on NK cells, CD16A undergoes a rapid down-regulation in expression by a proteolytic process following NK cell activation with various stimuli. In this review, the role of a disintegrin and metalloproteinase-17 (ADAM17) in CD16A cleavage and as a regulatory checkpoint is discussed...
February 20, 2019: Journal of Leukocyte Biology
Levent Renda, Tsung-You Tsai, Jung-Ju Huang, Ran Ito, Wei-Chuan Hsieh, Huang-Kai Kao, Shao-Yu Hung, Yenlin Huang, Yu-Chen Huang, Yu-Liang Chang, Ming-Huei Cheng, Kai-Ping Chang
OBJECTIVE: There is no useful tool to clinically predict the occurrence of osteoradionecrosis (ORN) of the mandible quantitatively. The aim was to investigate the risk factors, including different modalities of radiotherapy, for developing mandibular ORN in patients undergoing marginal mandibulectomy and postoperative radiotherapy. METHODS: Between January 2006 and December 2012, 167 subjects who underwent marginal mandibulectomy and postoperative radiotherapy with different modalities were enrolled...
February 20, 2019: Laryngoscope
Chathura B B Ratnayake, Renske Fles, I Bing Tan, Laura W J Baijens, Walmari Pilz, Cees A Meeuwis, Pauline H E Janssen-van Det, Rob van Son, Michiel W M Van den Brekel
OBJECTIVES: The aim of this study was to compare the relative compliance and the dermatological and pulmonary outcomes when the Provox Luna system (Atos Medical, Malmö, Sweden) is added during the night to the usual tracheastoma care of laryngectomized subjects. METHODS: This was a multicenter randomized crossover trial conducted in the Netherlands Cancer Institute, Erasmus Medical Center, and Maastricht University Medical Center in The Netherlands. The study included 46 laryngectomized subjects with prior heat and moisture exchanger (HME) and adhesive experience...
February 20, 2019: Laryngoscope
K Robin Yabroff, Ted Gansler, Richard C Wender, Kevin J Cullen, Otis W Brawley
Between 1991 and 2015, the cancer mortality rate declined dramatically in the United States, reflecting improvements in cancer prevention, screening, treatment, and survivorship care. However, cancer outcomes in the United States vary substantially between populations defined by race/ethnicity, socioeconomic status, health insurance coverage, and geographic area of residence. Many potentially preventable cancer deaths occur in individuals who did not receive effective cancer prevention, screening, treatment, or survivorship care...
February 20, 2019: CA: a Cancer Journal for Clinicians
Elaine Lai-Han Leung, Lian Xiang Luo, Ying Li, Zhong-Qiu Liu, Lan Lan Li, Dan Feng Shi, Ying Xie, Min Huang, Lin Lin Lu, Fu Gang Duan, Ju Min Huang, Xing Xing Fan, Zhong Wen Yuan, Jian Ding, Xiao Jun Yao, David C Ward, Liang Liu
Oncogenic KRAS is considered a promising target for anti-cancer therapy. However, direct pharmacological strategies targeting KRAS-driven cancers remained unavailable. The prenyl-binding protein PDEδ, a transporter of KRAS, has been identified as a potential target for pharmacological inhibitor by selectively binding to its prenyl-binding pocket, impairing oncogenic KRAS signaling pathway. Here, we discovered a novel PDEδ inhibitor (E)-N'-((3-(tert-butyl)-2-hydroxy-6,7,8,9-tetrahydrodibenzo[b,dfuran-1-yl)methylene)-2,4-dihydroxybenzohydrazide(NHTD) by using a high-throughput docking-based virtual screening approach...
February 20, 2019: International Journal of Cancer. Journal International du Cancer
Haifeng Yu, Shuaibin Wang, Haibo Zhu, Dapang Rao
Growing evidence suggested that the long noncoding RNAs (lncRNAs) regulate several pathophysiological processes in tumorigenesis and may be new biomarkers for tumor therapy. In this study, we studied the expression and role of lncRNA MT1JP in the development of bladder cancer. We demonstrated that the expression of MT1JP was downregulated in bladder tumor samples and cell lines. Ectopic expression of MT1JP suppressed cell proliferation, cycle, and invasion in bladder cancer. In addition, our result suggested that miR-214-3p overexpression decreased the luciferase activity of wild-type MT1JP but not mutated-type MT1JP and elevated expression of MT1JP decreased miR-214-3p expression in the bladder cancer cell...
February 20, 2019: Journal of Cellular Physiology
Amir Salek Farrokhi, Narges Darabi, Bahman Yousefi, Rafee Habib Askandar, Mansoreh Shariati, Majid Eslami
Recent studies demonstrated that a combination of the gut microbiome has the vital effect on the efficacy of anticancer immune therapies. Regulatory effects of microbiota have been shown in different types of cancer therapies such as chemotherapy and immunotherapy. Immune-checkpoint-blocked therapies are the recent efficient cancer immunotherapy strategies. The target of immune-checkpoint blocking is cytotoxic T lymphocyte protein-4 (CTLA-4) or blockade of programmed death-1 (PD-1) protein and its ligand programmed death ligand 1 (PD-L1) that they have been considered as cancer immunotherapy in recent years...
February 20, 2019: Journal of Cellular Physiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"